Amgen (AMGN): FY24 Q4 earnings call, Feb 4, 2025
No Kalshi or Polymarket word markets were listed for Amgen’s Feb 4, 2025 earnings call (FY24 Q4). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
2 matches for “VESALIUS-CV”; 2 quoted, at least 25 words apart.
…you describe the key lessons you expect to learn from the Repatha VESALIUS-CV outcome study results, how you can leverage those lessons across your portfolio,…
…broad use of Repatha in secondary prevention is a fantastic setup for VESALIUS-CV. As you know, this is a Phase III large cardiovascular outcome study…
Agents: this page as TSV at /api/v1/appearances/amgen:2025-02-04:earnings_call · words: /api/v1/brief?appearance=amgen:2025-02-04:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP